EMA Authorised: Ondibta (insulin glargine) — Gan & Lee Pharmaceuticals Europe GmbH

View source ↗

Summary

EMA authorised Ondibta, a brand-name insulin glargine, for treating diabetes mellitus; Marketing Authorisation Holder is Gan & Lee Pharmaceuticals Europe GmbH, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Ondibta (insulin glargine)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Gan & Lee Pharmaceuticals Europe GmbH. Decision date: 23/04/2026